NCT00913263 - An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

July 31, 2011

Conditions

Prostate Cancer

Interventions

DRUG

2-hydroxyflutamide (2-HOF) [Liproca Depot]

Ready made paste including 600 mg 2-HOF for injection as a single dose

DRUG

2-Hydroxyflutamide

The Product consists of two sterile components, one aqueous liquid and a dry powder, containing the active drug 2-Hydroxyflutamide (2-HOF. The two components were mixed under aceptic conditions to a paste prior to administration.

Trial Locations (2)

33520

Tampere University Hospital, Tampere

Unknown

Tampere University Hospital, Tampere